NuVasive Announces Preliminary Unaudited Full Year 2008 Financi...(r 2008 but the Company expects Osteocel ...),Health

The Company reiterated full year 2009 non-GAAP operating margins of 11% - 13% excluding stock based compensation, amortization of intangibles, intellectual property litigation fees, and impact of the Progentix Orthobiology BV investment.

NuVasive will not be holding a conference call to discuss its preliminary unaudited full year 2008 financial results. The Company will announce complete financial and operating details of its fourth quarter and full year ended December 31, 2008 and give detailed 2009 guidance after the market closes on February 25, 2008 and hold a conference call at 5:30 p.m. ET (2:30 p.m. PT).

Alex Lukianov, Chairman and Chief Executive Officer, said, "We are very pleased with the Company's revenue achievement in conjunction with our earnings performance in 2008, especially considering the challenging economic times. This week, we look forward to recognizing and rewarding our top performers at our National Sales Meeting."

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of biologics, cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and speci
'/>"/>